Roche receives US emergency approval for corona test – Roche shares firmer

Roche Holding AG has received emergency approval from the US FDA for its COVID-19 test for domestic use.

The test will be available nationwide from January, announced the Swiss pharmaceutical company. The kit provides accurate results for all known variants of the virus, including Omikron, in 20 minutes.

The test has been given priority by the FDA because Roche and SD Biosensor Inc. – with which Roche has a global distribution agreement – are able to supply large quantities and increase production to meet future demand. Roche has the capacity to produce tens of millions of tests per month, according to the company.

In Swiss retail, Roche participation certificates are temporarily up by 0.80 percent to 379.48 francs.


Leave A Comment